About 100 reports

ACCORDING TO THE WORLD HEALTH ORGANISATION (WHO), MENTAL DISORDERS SUCH AS ANXIETY AND DEPRESSION COST THE GLOBAL ECONOMY $## TRILLION EVERY YEAR.

  • OTC
  • World
  • Demand
  • Forecast
  • Market Size

A US MARKET REPORT ##.

  • Drug Delivery
  • Nasal Drug Delivery
  • OTC
  • Pharmaceutical
  • Therapy

DemeRx, Inc is developing noribogaine for the treatment of anxiety and nicotine abuse.

  • OTC
  • United States
  • World
  • Product Initiative
  • Omeros Corporation
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018

It offers pipeline portfolio such as asthma and allergy disorders, anxiety, epilepsy, and cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage.

  • OTC
  • Pharmaceutical
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • THEY CAN BE USED FOR ADDITIONAL INDICATIONS, SUCH AS DEPRESSION, BIPOLAR DISORDER, ANXIETY DISORDERS, AND NOCTURNAL ENURESIS.
  • 7.5 OTHER MINOR THERAPEUTIC CLASSES

THEY CAN BE USED FOR ADDITIONAL INDICATIONS, SUCH AS DEPRESSION, BIPOLAR DISORDER, ANXIETY DISORDERS, AND NOCTURNAL ENURESIS.

  • OTC
  • Allergan plc
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • OTC
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products
  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • OTC
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd
  • 5.2 Drivers

According to the updated report by the Anxiety and Depression Association of America, in 2017, approximately ##% of the adult population in North America had anxiety disorders.

  • OTC
  • North America
  • United States
  • World
  • Market Size
  • 5. All the trials included are unique trials.

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Clinical Trial
  • Drug Development
  • OTC
  • World
  • Alkermes plc
  • Indication Name
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

Report covers products from therapy areas Central Nervous System which include indications Insomnia, Nicotine Addiction, Alcohol Addiction, Anxiety Disorders, Binge Eating Disorder, Drug Addiction, Addiction, Dementia Associated With Alzheimer' s Disease, Major Depress

  • OTC
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 80 Trial Title

Anxiety Disorders, Depression, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorders, Post- Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorders (SAD), S

  • OTC
  • Therapy
  • World
  • Product Initiative
  • Pfizer Inc.
  • Clinical Trial profile. 810 Trial Title
  • Clinical Trial profile. 1258 Trial Title

Placebo for Treatment of Insomnia Associated with Anxiety when Used Concomitantly with Escitalopram (Lexapro) Ambien CR Vs.

  • Clinical Trial
  • OTC
  • Sleep Aid
  • World
  • Takeda Pharmaceutical Company Limited

PROPORTION OF MUSCLE SPASM TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF MUSCLE SPASM TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF MUSCLE SPASM TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COU

  • Clinical Trial
  • OTC
  • Pain Relief
  • World
  • Product Initiative
  • SMALL MOLECULES TO ANTAGONIZE GABAA1 FOR ALCOHOL ADDICTION AND ANXIETY - DRUG PROFILE

The company reported that the drug candidate can also be used for the treatment of schizophrenia, bipolar disorder social anxiety disorder, insomnia, Huntington s disease.

  • Antiseptics
  • OTC
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • PRESENTS KNOWN RISK FACTORS AND COMORBIDITIES FOR MIGRAINE.
  • RISK FACTORS AND COMORBIDITIES FOR MIGRAINE

ANOTHER STUDY FOUND A GREATER PREVALENCE OF MIGRAINE AMONG PEOPLE SUFFERING FROM GENERALIZED ANXIETY DISORDER (OR = ##. ##, ##% CI STROKE DEPRESSION BIPOLAR DISORDER =##. ##-##. ##).

  • OTC
  • Allergan plc
  • Amgen Inc.
  • Eli Lilly & Co.
  • Pfizer Inc.

Requip Paxil, an SSRI, was first approved by the FDA for the treatment of MDD in 1992 and later expanded to include generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, posttraumatic stress

  • Hospital
  • OTC
  • AstraZeneca PLC
  • Lilly Endowment Inc.
  • Pfizer Inc.

Reboxetine on Somatic and Visceral Sensitivity of Patients with Major Depressive Disorder: A Randomized, Double Blind Clinical Trial Effect of Escitalopram vs.

  • Clinical Trial
  • OTC
  • Pharmaceutical
  • Therapy
  • World

## ## ## ## ## ## China ## ## ## ## ## ## ## ## India ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Turkey Source: GlobalData' s Pharma Intelligence Center Clinical Trials Datab

  • Clinical Trial
  • OTC
  • World
  • Product Initiative
  • Pfizer Inc.
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
  • DORMANT PRODUCTS, H2 2017 (CONTD..1), H2 2017

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • OTC
  • Smoking Cessation
  • Therapy
  • United States
  • Product Initiative
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products
  • DORMANT PRODUCTS, H2 2017 (CONTD..1), H2 2017

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • OTC
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • OTC
  • Pharmaceutical
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • OTC
  • Pharmaceutical
  • World
  • Product Initiative
  • 2.6.3 CERVICAL INTRAEPITHELIAL NEOPLASIA

One study comparing infertile and fertile women found that infertile women experienced increased levels of distress, anxiety, depressive disorders and physiological disorders.

  • Genitourinary System Disease
  • Hormone
  • OTC
  • Company Financials
  • Forecast

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • OTC
  • Therapy
  • World
  • Total Prevalent Cases of Migraine (N)
  • presents the total prevalent cases of migraine in the 7MM in 2016 and 2026.

EpiCast Report: Generalized Anxiety Disorder - Epidemiology Forecast to 2024, October 2015, GDHCER##-##.

  • OTC
  • Japan
  • United States
  • World
  • Forecast

Spot shortages of life-saving medication causes anxiety for patients and caregivers.

  • Clinical Trial
  • OTC
  • Pharmaceutical
  • United States
  • Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • CLINICAL TRIAL PROFILE SNAPSHOTS

CIRCADIAN RHYTHM SLEEP DISORDERS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2019* CLINICAL TRIALS BY PHASE IN G## COUNTRIES CIRCADIAN RHYTHM SLEEP DISORDERS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2019* CIRCADIAN RHYTHM SLEEP DISORDERS THERAPEUTICS,

  • Clinical Trial
  • OTC
  • World
  • Product Initiative
  • Vanda Pharmaceuticals Inc.
  • 5. All the trials included are unique trials.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • OTC
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Gastrointestinal Drug
  • OTC
  • World
  • Merck & Co., Inc.
  • Clinical Trial profile. 438 Trial Title
  • Official Title

Placebo For Treatment Of Insomnia Associated with Anxiety When Used Concomitantly with Escitalopram (Lexapro) Ambien CR vs.

  • Clinical Trial
  • OTC
  • Pharmaceutical
  • Sleep Aid
  • World